CoChat

The social and economic burden of treatment-resistant schizophrenia: a systematic literature review

Kennedy, James L., Altar, C. Anthony, Taylor, Danielle L., Degtiar, Irina, Hornberger, John C. · 2014 · International Clinical Psychopharmacology

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.

Abstract

Patients with schizophrenia often fail to respond to an initial course of therapy. This study systematically reviewed the societal and economic burden of treatment-resistant schizophrenia (TRS). Studies that described patients with TRS published 1996-2012 were included if they collected primary data on clinical, social, or economic outcomes. All studies were independently reviewed and extracted by at least two investigators. Sixty-five studies were identified. Almost 60% (SD 18%) of patients failed to achieve response after 23 weeks on antipsychotic drug therapy. Patients with TRS had high rates of smoking (56%), alcohol abuse (51%), substance abuse (51%), and suicide ideation (44%). The incidence of severe adverse events to treatment was 4% (SD 7%). Mean quality of life for patients who were unresponsive or intolerant to treatment was ∼20% lower than that of patients in remission. Annual costs for patients with schizophrenia are $15 500-$22 300 and are 3-11-fold higher for patients with TRS. TRS remains common and costly, despite availability of many treatment options, and contributes to a significant loss in patient quality of life. Although estimates in the literature vary greatly, TRS conservatively adds more than $34 billion in annual direct medical costs in the USA.

Overview

Integrity signals

Registry

Crossref · 10.1097/yic.0b013e32836508e6

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 84 references

Cited by

See all 417

Metadata

Authors
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C.
Affiliations
  • University of Toronto (CA)
  • Stanford Medicine (US)
Corresponding author
Hornberger, John C.
Venue
International Clinical Psychopharmacology
Published
2014-03
Volume
29
Issue
2
Pages
63-76
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2036480935
Cited by
392
References
84
Citations by year
2026: 30 · 2025: 40 · 2024: 44 · 2023: 39 · 2022: 37 · 2021: 33 · 2020: 35 · 2019: 38 · 2018: 35 · 2017: 16 · 2016: 21 · 2015: 18 · 2014: 6
FWCI
10.67
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
treatment-resistant schizophrenia, economic burden, social burden, antipsychotic treatment response, treatment intolerance, smoking, alcohol abuse, substance abuse, suicidal ideation, adverse drug reactions, quality of life, health care costs, direct costs
MeSH terms
Costs and Cost Analysis, Drug Resistance, Humans, Psychiatric Status Rating Scales, Quality of Life, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Comorbidity, Randomized Controlled Trials as Topic, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. https://app.cochat.ai/papers/10.1097/yic.0b013e32836508e6
The paper
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014). The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e32836508e6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.